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Multiple Myeloma
Introduction
MicroRNA (miRNA, miR) are small non-coding RNA that
regulate gene expression at the post-transcriptional level and
are involved in critical biological processes, including cellular
growth and differentiation. Previous studies have shown that
miRNA expression is deregulated in myeloma cells as com-
pared to in normal plasma cells. Moreover, several miRNA
have been involved in the pathogenesis of multiple myeloma
(MM).1-3 In this sense, it has recently been shown that there is
a mechanism of p53 regulation through miRNA acting on
MDM2 expression; thus, miR-192, 194 and 215 re-expression
in myeloma cell lines induced degradation of MDM2 with
subsequent p53 up-regulation and cell growth inhibition.4 In
addition, miR-15a and 16 have also been shown to regulate
myeloma proliferation by inhibiting AKT and MAP-kinases,
and by reducing bone marrow angiogenesis.5
We have previously reported the down-regulation of 11
miRNA (miR-375, miR-650, miR-214, miR-135b, miR-196a,
miR-155, miR-203, miR-95, miR-486, miR-10a and miR-196b)
in MM samples compared to in normal plasma cells.6
Interestingly, only miR-214 and miR-375 were significantly
under-expressed in all the different cytogenetic subgroups
(including IGH translocations, RB deletions and normal fluo-
rescence in situ hybridization). miR-214 deregulation has been
observed in different types of cancer. Over-expression of
miR-214 has been reported in several tumors, such as
melanoma, ovarian cancer and gastric cancer.7-9 In contrast,
miR-214 was found to be down-regulated in breast cancer,
resulting in increased cell proliferation and invasion.10
Likewise, low miR-214 expression levels were associated
with metastasis and invasion of cervical tumors11 and it has
also been recently described that miR-214 is down-regulated
in primary central nervous system lymphomas.12
In order to investigate the potential involvement of miR-
214 in myeloma pathogenesis, we explored the functional
role of miR-214 in myeloma cells. We found that ectopic
expression of this miR-214 reduced cell growth and induced
apoptosis of myeloma cells. This effect was mediated by
interfering with the p53 signaling pathway through down-
regulation of p28/gankyrin protein and by inhibition of repli-
cation via decreasing the level of histone chaperone Asf1b.
Design and Methods
Cells and culture conditions 
The human myeloma cell lines, NCI-H929 and MM1S, were
acquired from the American Type Culture Collection (ATCC) and
JJN3 and RPMI-8226 from the Deuthche Sammlung von Mikroorganismen
und Zellkulturen (DSMZ). It was previously described that H929 and
MM1S cells have wild-type (wt) P53 and JJN3 and RPMI-8226 have
mutated/null P53.4 All cell lines were cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum and antibiotics (Gibco).
Cells were routinely checked for the presence of mycoplasma with
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MicroRNA have been demonstrated to be deregulated in multiple myeloma. We have previously reported that
miR-214 is down-regulated in multiple myeloma compared to in normal plasma cells. The functional role of miR-
214 in myeloma pathogenesis was explored by transfecting myeloma cell lines with synthetic microRNA followed
by gene expression profiling. Putative miR-214 targets were validated by luciferase reporter assay. Ectopic expres-
sion of miR-214 reduced cell growth and induced apoptosis of myeloma cells. In order to identify the potential
direct target genes of miR-214 which could be involved in the biological pathways regulated by this microRNA,
gene expression profiling of the H929 myeloma cell line transfected with precursor miR-214 was carried out.
Functional analysis revealed significant enrichment for DNA replication, cell cycle phase and DNA binding. miR-
214 directly down-regulated the expression of PSMD10, which encodes the oncoprotein gankyrin, and ASF1B, a
histone chaperone required for DNA replication, by binding to their 3'-untranslated regions. In addition, gankyrin
inhibition induced an increase of P53mRNA levels and subsequent up-regulation of CDKN1A (p21Waf1/Cip1) and
BAX transcripts, which are direct transcriptional targets of p53. In conclusion, MiR-214 functions as a tumor sup-
pressor in myeloma by positive regulation of p53 and inhibition of DNA replication. 
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MycoAlert kit (Lonza GmBH) and only mycoplasma-free cells
were used in the experiments. The phenotypic and cytogenetic
identities of the cell lines were verified by flow cytometry and flu-
orescence in situ hybridization before the experiments. Bone mar-
row samples were obtained from eight patients with myeloma
and four healthy subjects undergoing bone marrow harvest for
allogeneic transplantation. CD138+ plasma cells were isolated
(purity >95%) from the bone marrow samples using the
AutoMACS automated separation system (Miltenyi-Biotec). All
patients as well as healthy donors provided written informed con-
sent in accordance with the Helsinki Declaration, and the research
ethics committee of the University Hospital of Salamanca
approved the study.
Transfection with synthetic microRNA
Human myeloma cell lines were transfected with Pre-miR™
miRNA precursors pre-miR-214 or Pre-miR™ miRNA negative,
non-targeting control#1 (Ambion) at a 50 nM concentration, using
the nucleofector II system (Amaxa) with the C-16 program for H-
929 and JJN3, and the G-16 program for MM1S and RPMI-8226.
Transfection efficiency was assessed with Block-iT™ Fluorescent
Oligo (Invitrogen) by flow cytometry (Online Supplementary Figure
S1). Target gene down-regulation was monitored using the Pre-
miR™ miRNA Precursor Starter Kit (Ambion). 
RNA extraction and quantitative real-time polymerase
chain reaction analysis
RNA was extracted from the cell lines using Trizol reagent
(Invitrogen) according to the standard protocol. The RNA integrity
was assessed using an Agilent 2100 Bioanalyzer (Agilent
Technologies). To detect mature miR-214 expression levels, a
TaqMan quantitative real-time polymerase chain reaction (qRT-
PCR miRNA) assay (Applied Biosystem) was performed. The rel-
ative expression of mature miR-214 levels normalized to the
RNU43 endogenous control was determined using the 2−ΔCt
method. Each measurement was performed in triplicate. 
To detect the target genes (mRNA expression), total RNA (1 mg)
was reverse transcribed to cDNA using SuperScript™ III First-
Strand Synthesis SuperMIx (Invitrogen). For PSMD10, ASF1B and
P53 expression, iQ™ SYBR® Green Supermix kit (BioRad) was
used. SYBR green qRT-PCR was performed using the Bio-Rad iQ5
PCR detection system with the following gene-specific primers:
GAPDH, forward 5’ GCTTCGCTCTCTGCTCCTCCTGT-3’ and
reverse 5’- ACTGGACTGACCTGGTCCAC-3’; PSMD10, for-
ward 5’-GGTGTCCCAAGGAGCAAGTA-3’ and reverse 5’
ACACTGGGGACAACAACACA-3’; ASF1B, forward 5’-GAG-
GCTTTCTTGGTCAGTGC-3’ and reverse 5’-TCCTGCTGAT-
CACACCTCTG-3’; P53, forward 5’ GGCCCACTTCACCG-
TACTAA-3’ and reverse 5’-GTGGTTTCAAGGCCAGATGT-3;
MAPK3, forward 5’- ACTATGACCCGACGGATGAG-3´ and
reverse 5’- CTAACAGTCTGGCGGGAGAG-3´; SCAMP3, for-
ward 5´-TTTGAGACCCGGGAGCCACCA-3´ and reverse 5´-
AAAGCCCAAAGCCTGCGCCA-3´; PEMT, forward 5´-
TCGTCGGTGACCTGTGGGACT-3´and reverse 5´-CCTGCGT-
GAAGCAGTGCGAG-3´; CDC7AL, forward 5´-TGGC-
GACTCGCTACCAGATCCC-3´ and reverse 5´-GCGCACATC-
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Figure 1. Expression level of
miR-214 in myeloma cells. (A)
Comparison of miR-214
expression by qRT-PCR
between normal plasma cells
(NPC) and MM cell lines. (B)
Expression of miR-214 after
72 h of 5-aza-dC treatment.
Data represent the average of
three independent experi-
ments ±SD. (C) Level of miR-
214 after transfection with
negative, non-targeting con-
trol and pre-miR-214 in H929
(left panel) and JJN3 (right
panel) cells. Expression of
miR-214 was normalized to
RNU43 and presented as 2(-ΔCt). 
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CTGCTGTTTCCCT-3´; SEC24C, forward 5´-GGAGCCGGGA-
GATAATCTGAA-3 and reverse 5´-GGCAGCCTTTGCATCT-
GAAC-3´; ORC1L, forward 5´- TCTCAAGCCTAGAACGCCAC-
3´ and reverse 5´- TGGCCTGTTAGCTTCTGCAA-3´. Expression
of BAX, MCM2, MCM4, MCM6, MCM7 was assessed using
Dharmacon Solaris qPCR and CDKN1A(p21/Waf1) using TaqMan
expression assays, each normalized to the respective Dharmacon
Solaris or TaqMan GAPDH expression assay. Relative gene expres-
sion was calculated using the 2−ΔCt method.
5-aza-2′-deoxycytidine treatment
JJN3 and H929 cells were subcultured at a density of 7x105
cells/mL (viability > 95 %) the day before the experiment. These
cells were then exposed to 5-aza-2′-deoxycytidine (5-aza-dC;
Sigma-Aldrich) 1 mM for 72 h. The corresponding amount of
dimethlysulfoxide (DMSO; Sigma-Aldrich) was added to the neg-
ative controls. 
Cell proliferation assays
Cell viability was evaluated by a trypan blue exclusion test
(Invitrogen) and by a CellTiter-Glo® luminescent cell viability
assay based on the amount of ATP present (Promega), in accor-
dance with the manufacturer’s protocol. Cell growth was exam-
ined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) colorimetric assay (Sigma-
Aldrich) as previously described.13 BrdU incorporation was meas-
ured using a BrdU Cell Proliferation Kit according to the manufac-
turer’s protocol (Millipore). BrdU was incorporated over 24 h.
Apoptosis assays 
Apoptosis was measured using an annexin V-fluorescein isoth-
iocyanate/propidium iodide (PI) double staining (Immunostep)
according to the manufacturer’s procedure. Mitochondrial mem-
brane depolarization was evaluated using DiOC6(3)/PI dual stain-
ing (Sigma-Aldrich). Cells were acquired on a FACSCalibur flow
cytometer (Becton Dickinson) and analyzed with the CellQuest
program. Caspases 3/7, 8 and 9 activity was evaluated by
Caspase-Glo® 3/7, Caspase-Glo® 8 and Caspase-Glo® 9 Assays
(Promega), respectively, according to the manufacturer’s protocol.
In the assays 20,000 cells/well were incubated with the reagents at
room temperature for 1 h in the case of caspase 3/7 and 2 h for cas-
pases 8 and 9. Light intensity was measured in each well using a
Tekan Infinite® F500 microplate reader.
Cell cycle analysis
Cells were washed in phosphate-buffered saline, fixed in 70%
ethanol overnight, washed with phosphate-buffered saline again
and resuspended in 500 mL of PI/RNASE staining solution
(Immunostep) and incubated for 20 min at room temperature in
the dark. Samples were analyzed by FACSCalibur flow cytometry.
For each sample a signal from 30,000 cells was acquired and the
cell cycle was analyzed with ModFit™ software. 
Immunoblotting
Whole cell lysates were collected using RIPA buffer (Sigma-
Aldrich) containing protease inhibitors (Complete Protease
Inhibitor Cocktail Tablets, Roche) and phosphatase inhibitors
(Phosphatase Inhibitor Cocktail A and B, Santa Cruz
Biotechnology). Protein concentration was measured using the
Bradford assay (BioRad). Protein samples (40 mg/lane) were sub-
jected to sodium dodecyl sulphate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred to 0.45 mm polyvinyli-
dene fluoride (PVDF) membranes (BioRad). The primary antibod-
ies used for immunoblotting were anti-Asf1b and anti-p-Mdm2
(Cell Signaling), anti-gankyrin, anti-p53, anti-Mdm2 and anti-p21
(Santa Cruz Biotech), and anti-b-actin (Sigma-Aldrich) as an inter-
nal control for protein loading. The membranes were then washed
and subsequently incubated with the secondary horseradish per-
oxidase-linked anti-mouse IgG and anti-rabbit IgG antibodies
(PierceNet) (1:10000). Chemiluminescence was detected using the
Amersham ECL Plus™ Western Blotting Detection Reagent (GE
Healthcare).
Gene expression profiling
Total RNA was amplified, labeled and hybridized to Human
Gene 1.0 ST Array (Affymetrix) as previously reported.6 The
integrity of the RNA was verified with an Agilent 2100 Bioanalyzer.
Full microarray data are available at the Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=xjcdlmem-
keeemps&acc=GSE35948). Bioinformatic analysis was carried out
using DNA-Chip Analyzer software (DChip).14 The comparison
criteria used in dChip analysis were fold change E/B>2 or B/E>2,
mean difference E-B>100 or B-E>100 and the lower 90% confi-
dence bound of fold-change was used. Gene-annotation enrich-
ment analysis was performed with version 6.7 of the Database for
Annotation, Visualization and Integrated Discovery (DAVID)
(http://david.abcc.ncifcrf.gov/).15,16
Computational microRNA target prediction
Three different databases (Targetscan
http://www.targetscan.org/,17,18 miRDB http://mirdb.org/,19,20 and
miRANDA http://www.microrna.org/)21 were used to identify poten-
tial miR-214 target genes. 
Luciferase reporter assay
The double-stranded oligonucleotides corresponding to the
wild-type (WT-3’UTR) or mutant (MUT-3’UTR) miR-214 binding
site in the UTR of PSMD10 (NM_002814) or ASF1B (NM_018154)
were synthesized (Sigma-Aldrich) and ligated between the PmeI
and Xbal restriction sites of the pmirGLO vector (Promega). The
oligonucleotides sequences are presented in Online Supplementary
Table S1. For luciferase assays, HEK293 cells were transfected with
500 ng of the above constructs and co-transfected with 25 nM
miRNA precursor molecule by nucleofection using the HEK293
cell line program in the Amaxa II nucleofector system. Twenty-
four hours after transfection cells were collected and Firefly and
Renilla luciferase activities were measured using the Dual-Glo®
Luciferase Assay System (Promega) according to the manufactur-
er’s protocol. Measurements were performed on a Tekan Infinite®
F500 microplate reader. Firefly luciferase activity was normalized
to Renilla luciferase activity.
Statistical analysis
The two-sided Student’s t test was used to analyze differences
in experiments. Data are reported as mean values ± SD of at least
triplicate determinations. The Mann-Whitney U test was used to
identify statistically significant differences between normal plas-
ma cells and those from patients with MM. P values < 0.05 were
considered statistically significant. All statistical analyses were
conducted using the SPSS 15.0 statistical package (SPSS).
Results
Involvement of DNA methylation in down-regulation 
of microRNA-214
In order to corroborate the down-regulation of miR-214
previously reported in primary MM cells, we measured
the level of miR-214 in a set of MM cell lines (MM1S,
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H929, OPM-2, JJN3 and RPMI 2886) and compared it to
the level in normal plasma cell samples (n=3) using
miRNA TaqMan qRT-PCR. miR-214 was down-regulated
in all MM cell lines tested (Figure 1A). Since the 1q region,
in which miR-214 is located, is commonly gained in MM,
we hypothesized that epigenetic mechanisms could be
involved in the under-expression of miR-214 in MM. To
address this question we treated H929 and JJN3 cells with
the DNA demethylating agent 5-aza-dC and quantified
the expression of miR-214. After 5-aza-dC treatment,
miR-214 expression was increased more than 2-fold in
both myeloma cell lines (Figure 1B).
Over-expression of microRNA-214 reduces growth 
of myeloma cells
To investigate the functional role of miR-214 expression
in MM, we carried out gain-of-function experiments in
H929 and MM1S (wt P53) and JJN3 and RPMI-8226 (P53
mutated/null). The miR-214 over-expression persisted for
up to 5 days (Figure 1C). Our results showed that over-
expression of miR 214 inhibited cell growth, as assessed
by trypan blue counting and quantification of ATP levels,
in the four cell lines with respect to in the non-targeting
control although the growth inhibitory effect started 24 h
later in P53 mutated/null cells (JJN3 and RPMI-8226) than
in P53 wt cells (H929 and MM1S) (Figure 2A and B, and
Online Supplementary Figure S2A, B). 
To assess whether the decrease of cell growth was the
result of apoptosis induction, annexin V-positive cells
were quantified as well as DiOC6(3) negative-cells in order
to determine the involvement of mitochondria in cell
death. Ectopic transfection of miR-214 induced apoptosis
miR-214 expression and myeloma cell growth
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Figure 2. Overexpression of miR-214 reduces cell growth and induces apoptosis in myeloma cells. H929 cell line (left panel) and JJN3 cell
line (right panel). (A) Relative number of live cells in a time course evaluated by trypan blue counting after miR-214 or non-targeting control
(NC) transfection. Data are the average ± SD of three independent experiments. (B) Proliferation evaluated by ATP quantitation (CellTiter-
Glo®) of myeloma cells transfected with miR-214. The results are presented as the mean ± SD of three different experiments and consid-
ering the result after non-targeting control (NC) transfection as 100%. (C) Apoptosis examined by annexin V/PI assay and (D) mitochondrial
membrane depolarization after miR-214 or NC transfection. Data are the mean ± SD of three separate experiments. (E) BrdU incorporation
24 and 48 h after miR-214 transfection. The results were quantified as described for panel B. (F) Cell cycle changes after 24 h of transfection
with miR-214 or NC. Results are the mean of three independent experiments.  *P<0.05; **P<0.01. 
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at 72 h at significant levels in H929 and JJN3 cell lines
(P<0.01) (Figure 2C). In addition, using DiOC6(3), a
decrease in mitochondrial membrane potential was
observed after miR-214 transfection (Figure 2D). To evalu-
ate the role of caspases in the induction of apoptosis, the
levels of activity of caspase 3/7, 8 and 9 were analyzed in
H929 and JJN3 cell lines after transfection with miR-214 or
non-targeting control. Transfection with miR-214 induced
executioner caspases 3 and 7 in both cell lines, although
this effect was less strong for P53 mutated/null JJN3 cells
(Online Supplementary Figure 3A). Caspase 8 (Online
Supplementary Figure 3B) and caspase 9 (Online
Supplementary Figure 3C) were also activated by miR-214
in both cell lines (JJN3 and H929) suggesting the activation
of both extrinsic and intrinsic pathways of apoptosis. 
To gain additional insights into the nature of the growth
inhibitory effects after miR-214 transfection, we assessed
cell proliferation. MiR-214 over-expression reduced the
proportion of BrdU-positive cells by 58% in H929 cells
and by 80% in JJN3 cells (P<0.01) in comparison with non-
targeting controls (Figure 2E). This result was consistent
with the decrease in S phase in cells transfected with miR-
214 compared to the non-targeting control (P<0.05)
(Figure 2F).
Identification of microRNA-214 targets 
by microarray analysis
To elucidate the molecular basis of the miR-214 down-
regulation, we compared the gene expression profile of
H929 cells transfected with synthetic miR-214 and that of
the non-targeting control. Overall, 64 genes were differen-
tially expressed by >2-fold after ectopic (69 probesets)
transfection of miR-214 (Online Supplementary Table S2).
Among them, 44 (69%) were under-expressed. Functional
analysis using DAVID software revealed significant
enrichment (P<0.05 after Benjamini’s multiple test correc-
tion) for DNA replication, cell cycle phase and DNA bind-
ing. In order to identify miR-214 predicted targets among
the genes down-regulated by miR-214 transfection, we
crossed these genes with databases of putative direct tar-
gets of this miR-214. We only considered those mRNA
predicted by two of the three different algorithms used
(TargetScan, miRDB and miRANDA). Genes that were
down-regulated most significantly and were predicted as
miR-214 targets are presented in Online Supplementary
Table S3. The expression of these genes after miR-214
transfection was further validated by qRT-PCR in four
MM cell lines (Online Supplementary Figure S4).
Validation of microRNA-214 targets in myeloma cells
Among the genes predicted as miR-214 targets which
were down-regulated after transfection of H929 cells with
miR-214, we chose to validate in more detail PSMD10 and
ASF1B. PSMD10, also named 26S proteasome non-
ATPase regulatory subunit 10, acts as an oncoprotein
(p28/gankyrin) involved in the negative regulation of
tumor suppressors RB1 and P53.22 ASF1B, which is
required for proper DNA replication and nucleosome for-
mation, was the most down-regulated mRNA after miR-
214 transfection.23
To validate gene expression profiling results, PSMD10
and ASF1B expression was assessed by qRT-PCR and
western blotting after transfecting MM cell lines with
miR-214 precursor. PSMD10 and ASF1B mRNA levels
were found to be dramatically decreased in H929, MM1S
and RPMI-8226 cells transfected with miR-214 in compar-
ison with the levels in the non-targeting control (Figure
3A,B). When we assessed the effect of miR-214 on protein
I. Misiewicz-Krzeminska et al.
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Figure 3. Validation of miR-214 tar-
gets in myeloma cells. (A) mRNA level
measured by qRT-PCR of PSMD10 and
(B) ASF1B in H929 cells 24 h after
transfection with miR-214 precursor
or NC normalized to GAPDH.
**P<0.01. The results are presented
as the mean ± SD of three different
experiments. (C) Level of Psmd10
(gankyrin) and (D) Asf1b proteins by
western blotting in H929 and JJN3
cells after transfection with miR-214
or NC at 24, 48 and 72 h. The panels
show the results of an experiment
that was repeated twice. 
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levels, western blotting showed a decrease of gankyrin
(encoded by PSMD10) and Asf1b proteins after transfec-
tion (Figure 3C and D for H929 and JJN3, Online
Supplementary Figure S5 for MM1S and RPMI-8226). To
further validate these results on primary MM samples, we
evaluated PSMD10 and ASF1B expression in myeloma cell
samples obtained from eight MM patients who, according
to previous miRNA profiling analysis, had low miR-214
levels.6 The expression values of PSMD10 and ASF1B
were significantly higher in MM cases than in normal plas-
ma cells: median value of 0.042 (range, 0.029-0.074) versus
median, 0.009 (range, 0.006-0.025) for PSMD10 (P=0.004),
and median value of 0.019 (range, 0.009-0.033) versus
median, 0.009 (range, 0.002-0.013) for ASF1B (P=0.048)
(Online Supplementary Figure S6).
PSMD10 and ASF1B are direct targets of microRNA-214
According to the prediction algorithms, miR-214 has
one putative binding site (8-mer) in the PSMD10 3’UTR
(Figure 4A) and another (8-mer) in the ASF1B 3’UTR
(Figure 4B). It should be noted that based on the
TargetScan 5.2 algorithm, it was predicted that mir-214
had the strongest effect on PSMD10 expression among all
miRNA (total context score: -0.39). To determine whether
PSMD10 and ASF1B transcripts were direct targets of
miR-214, we carried out luciferase reporter assays in
HEK293 cells. We cloned the 3’UTR of PSMD10 and
ASF1B harboring the complementary sequence to the
miR-214 seed sequence in a reporter plasmid vector. In
parallel, the same PSMD10 and ASF1B sequences with
four point mutations were cloned in the same reporter
plasmid. Data from these experiments revealed that
luciferase activity of the wt PSMD10 and ASF1B 3’UTR
luciferase reporter in cells co-transfected with pre-miR-
214 was significantly lower (P<0.01) than that of those
transfected with non-targeting control miRNA, whereas
luciferase activity of constructs in which the miR-214
binding site was mutated was not affected by miR-214
over-expression (Figure 4C,D). Taken together these
results demonstrate that miR-214 modulates PSMD10 and
ASF1B expression through the consensus miR-214 binding
site in the PSMD10 and ASF1B 3’UTR. 
MicroRNA-214 increases the level of p53 
by down-regulation of PSMD10
PSMD10 encodes the gankyrin protein which functions
as a negative regulator of p53 by modulating MDM2 activ-
ity.22 This fact prompted us to investigate the effect of the
interaction between miR-214 and gankyrin on p53 status.
First, as an internal control, we used a small antagonist of
the MDM2/p53 interaction, Nutlin-3a, which leads to sta-
bilization of p53.24 Nutlin-3a inhibits the MDM2/p53
miR-214 expression and myeloma cell growth
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Figure 4. miRNA-214 targets the 3'UTR of ASF1B and PSMD10. (A) Schematic diagram of the miR-214 predicted site on the PSMD10 and
(B) ASF1B 3'UTR. 3’UTR of both genes have one binding site for miR-214 predicted by TargetScan which is the exact match to positions 2-
8 of the mature miRNA (the seed + position 8) followed by an ‘A’. (C) Luciferase activity in HEK293 cells co-transfected with pre-miR-NC or
pre-miR-214 and plasmid pmiR-Glo with the putative miR-214 binding site of PSMD10 and (D) ASF1B cloned downstream of the luciferase
reporter gene. Luciferase activity was normalized using Renilla. The results are presented as the mean ± SD of three different experiments.
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interaction by binding to the part of the MDM2 protein
that interacts with p53.25 After incubating H929 cells with
Nutlin-3a, we observed an increase in P53 mRNA and in
the level of the protein (Figure 5A,B). The activation of p53
induced MDM2 and pMDM2 accumulation, and p21
expression, as expected (Figure 5B). Further, we investigat-
ed the effect of miR-214 over-expression and consequent
gankyrin down-regulation on the level of p53.26 Ectopic
expression of miR-214 in H929 and MM1S cells, which
express wt P53, resulted in an increase of P53 mRNA lev-
els (Figure 5C). Subsequently, downstream transcriptional
targets such as, CDKN1A (p21Waf1/Cip1) and BAX were
activated (Figure 5C).
MicroRNA-214 can interfere with the formation 
of the replication initiation complex
It has been documented that Asf1b, together with
MCM 2, 4, 6 and 7 proteins and histones H3-H4, forms a
complex that is required for the formation of the replica-
tion fork.27 The eukaryotic MCM2-7 complex is recruited
onto origins of replication during the G1 phase of the cell
cycle and acts as the main helicase at the replication fork
during the S phase.28 Since gene expression profiling of
cells transfected with miR-214 revealed down-regulation
of many genes involved in the replication process, such as
ASF1B, MCM2 and ORC1L (Online Supplementary Table
S3), we evaluated the level of MCM2-7 transcripts by
qRT-PCR. We detected not only down-regulation of the
expression of MCM2, but also of MCM 4, 6 and 7 genes,
after miR-214 transfection (Online Supplementary Figure
S7A). Moreover, we confirmed the down-regulation of
MCM2 and MCM4 in JJN3, MM1S and RPMI-8226 cells
(Online Supplementary Figures S4E and S7B).
Discussion
In the present study, we show that miR-214 could func-
tion as a tumor suppressor in myeloma by targeting
PMSD10 and ASFB1, which are involved in essential bio-
logical pathways. The mechanism responsible for down-
regulation of miR-214 is unlikely to be explained by loss of
the chromosome region in which the gene encoding this
miRNA is located (1q24), since 1q is gained in more than
60% of MM patients. According to our results with 5-aza-
dC treatment, it seems possible that epigenetic silencing
by DNA methylation could be involved in the down-reg-
ulation of miR-214 level in myeloma cells. Methylation of
DNA has also been shown to be important in the regula-
tion of several miRNA in MM, such as miR-203, 194-2,
192 and 34a.4,29,30
The restoration of miR-214 in myeloma cell lines
decreased proliferation and induced apoptosis. Other
miRNA have been reported to provoke similar effects in
MM. Thus, miR-15a and 16 regulate cell proliferation of
MM cells by inhibiting AKT serine/threonine-protein-
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Figure 5. Effect of miR-214 restoration on the P53 pathway. (A) P53 mRNA expression normalized to GAPDH using qRT-PCR in H929 cells
incubated with Nutlin-3a compared to untreated cells (control, C). Experiments were performed in triplicate. (B) Western blotting of p53,
MDM2, p-MDM2 and p21 protein expression in H929 cells treated with Nutlin-3a. Results are representative of one experiment that was
repeated twice. (C) mRNA level of P53, BAX, and CDKN1A (P21Cip1/Waf1) assessed by qRT-PCR after H929 and MM1S transfection with
miR-214 precursor or NC. The results are shown as an average of three experiments after normalization to GAPDH. *P<0.05, **P<0.01. 
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kinase (AKT3), ribosomal-protein-S6, MAP-kinases and
NF-κB-activator MAP3KIP3.5 MiR-203, which is epigenet-
ically silenced in MM, has been reported to act as a tumor
suppressor.29 Moreover, ectopic re-expression of miR-29b,
down-regulated in MM, resulted in induction of caspase-
dependent apoptosis in myeloma cells.31
In order to discover miR-214 target genes that could be
involved in the biological pathways regulated by this
miRNA, we used a gene expression profiling strategy.
PSMD10was one of the predicted targets down-regulated
after miR-214 transfection. Using gain-of-function experi-
ments and luciferase reporter assays we observed that
ectopic transfection of miR-214 decreased the level of
gankyrin protein by directly targeting PSMD10.
Moreover, as a consequence of gankyrin down-regulation
in cells with wt P53, we observed an increase of P53
mRNA levels and subsequent up-regulation in CDKN1A
(p21Waf1/Cip1) and BAX transcripts, which are direct
transcriptional targets of p53.26 One of the oncogenic
mechanisms attributed to gankyrin is to recruit the
MDM2/p53 complex to the proteasome and foster the
turnover of p53 in an MDM2-dependent manner. In this
process, gankyrin protein binds to MDM2 protein and
enhances the ability of MDM2 to ubiquitinate p53.32 Thus,
it has been shown that over-expression of gankyrin blocks
p53-dependent apoptosis in human bone osteosarcoma U-
2 OS cells that have wt P53.22 When gankyrin was silenced
in hepatocellular carcinoma cell lines with wt and mutated
P53, a different phenotype was induced in the wt P53
cells, with up-regulation of p53 levels and subsequent acti-
vation of caspase 9 and induction of apoptosis.33 Our
results showed stronger inhibition of cell growth and a
greater pro-apoptotic effect after miR-214 transfection in
cell lines with wt and functional P53 than in mutated P53
cell lines. However, apoptosis was also induced in JJN3
cells, which although they do not carry the P53 mutation,
do have impaired activity of the p53 pathway.4,34 These
data indicate that the role of gankyrin might not be
restricted to the interaction with p53. This hypothesis has
been suggested in hepatoma cells.35
Mutations of P53 are relatively rare in newly diagnosed
MM, occurring in approximately 5% of patients, although
the frequency of mutations appears to increase with
advancing disease.36,37 On the other hand, deletion (mainly
mono-allelic) of P53 occurs in about 10% of MM cases.36,38
In spite of this rather low incidence, p53 may play a
broader role in myeloma pathogenesis than previously
thought, since an imbalance in p53 with biological conse-
quences in myeloma cells can also be induced through
post-transcriptional mechanisms. Thus, Pichiorri et al.
observed that the reinforced expression of miRNA-192, -
194 and -215 induced dramatic down-regulation of
MDM2 together with p53 over-expression and p21 activa-
tion. These miRNA can, in turn, be transcriptionally acti-
vated by p53 as demonstrated by Nutlin-3a treatment.4 In
this regard, Nutlin-3a, a small inhibitor of MDM2, was
previously described to stabilize p53 level in myeloma
cells by abolishing its degradation forced by MDM2.24 The
fact that bortezomib leads to an increase in the level of
p53 protein, by inhibition of the proteasome that normally
degrades p53, and subsequently to activation of the p53
pathway, underscores the relevance of p53 regulation in
the pathogenesis of MM.39 Nutlin-3a and bortezomib have
been reported to have a synergistic anti-myeloma effect.40
Although the activity of a single miRNA compared to the
use of synthetically generated compounds, such as Nutlin-
3a or bortezomib, is gentler, our results support the impor-
tance of the p53/MDM2 regulatory mechanism in MM. 
A significant enrichment for DNA replication category
was found among the genes deregulated in H929 cells
after ectopic transfection with miR-214. Interestingly,
three of the genes, ASF1B, MCM2 and ORC1L, involved
in DNA replication and down-regulated after miR-214
transfection were miR-214 predicted targets. It has been
described that Asf1b, together with MCM 2, 4, 6 and 7
proteins and histones H3-H4, forms a complex that is
required for the formation of the replication fork.27 The
MCM2-7 complex serves as the eukaryotic replicative
helicase, the molecular motor that both unwinds duplex
DNA and powers fork progression during DNA replica-
tion.41 In the present study, qRT-PCR analysis revealed
down-regulation of MCM 2, 4, 6 and 7 genes after over-
expression of miR-214 in MM cells. The restoration of
miR-214 into myeloma cells also decreased the mRNA
and protein levels of Asf1b. Moreover, we were able to
demonstrate in a direct 3’UTR luciferase assay that this
decrease was a result of direct targeting of 3’UTR of
ASF1B by miR-214. The function of Asf1b protein, a his-
tone H3-H4 chaperone, is to deliver histones to the repli-
cation sites. A decrease of Asf1b has been described in
various types of quiescent human cells.42 Asf1b is a spe-
cific marker for discriminating between cycling and non-
cycling cells and is a marker of proliferation status in
breast cancer. Tumor cells transfected with siRNA against
Asf1b decreased the ability to form colonies. The genes
that were found to be affected after silencing of Asf1b
were mostly involved in proliferation, and as a conse-
quence also in cell survival. Moreover, breast cancer
patients with high expression of Asf1b had a poorer
prognosis and higher level of metastasis.42 Interestingly,
Asf1b is one of the proteins involved in the activity of
bortezomib, although its precise function requires further
validation.43 Taken together, these results indicate that
miR-214 interferes in the replication process of myeloma
cells.
In conclusion, we demonstrated that the low expression
of miR-214 in MM contributes to the loss of cell growth
control. The restoration of miR-214 expression in myelo-
ma cells induced apoptosis and inhibited proliferation by
targeting the p53/MDM2 interaction and DNA replication
pathway.
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